• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

SMG 1430.14

FDA STAFF MANUAL GUIDES, VOLUME II - DELEGATIONS OF AUTHORITY

ADMINISTRATIVE - PERSONNEL

AUTHORITY TO APPROVE PAYMENT OF SUPERVISORY DIFFERENTIALS

Effective Date: 12/10/2004

[PDF Version]

1. AUTHORITY DELEGATED:

a. To approve new or increase existing supervisory differential amounts.

b. To recommend new or increase existing supervisory differential amounts.

c. To approve the reduction or termination of supervisory differentials for both mandatory and non-mandatory actions.

d. To recommend the reduction or termination of supervisory differentials for both mandatory and non-mandatory actions.

2. TO WHOM DELEGATED:

a. Items (a) and (c) above are delegated to the Deputy Commissioners; Chief Counsel and Deputy Chief Counsels; Associate Commissioners; Center/Office Directors; Director, Office of Management Programs; Director, Office of Management, CDER; Director, Office of Management, CBER; Associate Director for Management and Systems, CDRH; Director, Office of Management, CVM; Deputy Center Director for Management, NCTR, and Associate Director for Management Services, NCTR; Director, Office of Resource Management, ORA; and Director, Office of Executive Operations, Office of Management, Office of the Commissioner.

b. Items (b) and (d) are delegated to officials below the level of the officials listed in paragraph 2.a.

All previous delegations of authority inconsistent with the provisions of this delegation are superseded.

3. LIMITATIONS:

The total continuing pay of the supervisor receiving the differential may not exceed the total continuing pay of the highest paid non-GS subordinate employee by more than 3%.

4. REDELEGATION AND CERTIFICATION.

The authority delegated in Item (a), (b), (c), and (d) may be further redelegated; however, the approving official in (a) and (c) must be a higher level official than the recommending official in (b) and (d).

Any redelegation must be in writing and specify the nature and extent of the authority redelegated. Delegates must be certified as knowledgeable about the legal, regulatory, and policy requirements regarding the subject authority. A copy of the redelegation of this authority must be furnished to the Director, Office Management Programs (HFA-400) and to the FDA Delegations Officer (HFA-340). Delegates are subject to compliance audits.

5. EFFECTIVE DATE.

This delegation was signed by Jeffrey M. Weber, Associate Commissioner for Management, effective December 10, 2004.